Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique
NCT06365359 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-03-31
Summary
Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone.
Epidemiological studies conducted in the French West Indies have shown that exposure to chlordecone at the levels observed is associated with an increased risk of developing several diseases, including premature birth and prostate cancer. Many of the adverse effects associated with chlordecone could be explained by its estrogenic hormonal properties, and systemic lupus erythematosus (SLE) is an autoimmune disease whose sensitivity to estrogen is well known and is reflected by 1) its clear predominance in women, 2) its predominance in women of childbearing age, 3) its risk of exacerbation in the event of pregnancy.
Chlordecone has the potential to modify the activity of SLE through mechanisms other than its pro-estrogenic effects. In rats, chlordecone was observed to induce alterations such as a reduction in lymphocyte count, thymic atrophy, and a decrease in splenic germinal centers and NK cells.
In a mouse model of systemic lupus erythematosus (SLE), exposure to chlordecone results in increased production of immune complexes and anti-DNA antibodies, which are markers of disease activity and monitoring.
Chlordecone also has a cellular effect that reduces the apoptosis of potentially auto-reactive lymphocytes and stimulates the production of GM-CSF, IL-2, TNF-alpha, and IFN-gamma. The latter is central to the pathophysiology of SLE. While experimental studies suggest a potential impact of chlordecone on SLE, no human studies have been conducted to date, and the chlordecone impregnation of lupus patients in Martinique remains unknown.
The most serious and feared complication of SLE is kidney damage. Kidney damage from the disease and the necessary immunosuppressive treatments can lead to significant morbidity and mortality, including death and end-stage chronic renal failure. Therefore, it is important to manage the disease carefully. Suspected lupus nephritis is confirmed by a renal biopsy, which allows for formal diagnosis and categorization into several classes. Suspected cases are identified by a proteinuria to creatininuria ratio greater than 0.5 g/g (or 24-hour proteinuria greater than 0.5g).
The objective of this project is to determine whether there is a positive association between lupus nephritis occurrence in patients followed by the internal medicine department of the Martinique University Hospital and organochlorine pesticide chlordecone impregnation.
Conditions
- Systemic Lupus Erythematosus
- Renal Disease
Interventions
- OTHER
-
Blood sample for analysis of plasma of organochlorine pesticides concentration
A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
- OTHER
-
Blood sample for cell collection
A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM. This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells).
Sponsors & Collaborators
-
Institut Pasteur de Guadeloupe
collaborator UNKNOWN -
Centre de Ressources Biologiques de la Martinique (CeRBiM)
collaborator UNKNOWN -
University Hospital Center of Martinique
lead OTHER
Principal Investigators
-
Benoît SUZON, PhD · University Hospital Center of Martinique
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-02
- Primary Completion
- 2026-07-02
- Completion
- 2026-09-02
Countries
- France
More Related Trials
-
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
NCT06859619 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
NCT01214876 ·Status: COMPLETED
-
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
NCT04072874 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909
NCT01351948 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
NCT01422954 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali
NCT04329104 ·Status: COMPLETED ·Phase: PHASE2
-
Sero-epidemiology of Priority Arboviruses in French Guiana
NCT03210363 ·Status: COMPLETED ·Phase: NA
-
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-malaria MAb in Malian Children
NCT05304611 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
NCT04238689 ·Status: COMPLETED ·Phase: PHASE1
-
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020 ·Status: COMPLETED ·Phase: PHASE2
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
NCT04888130 ·Status: COMPLETED
-
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
NCT02098590 ·Status: COMPLETED ·Phase: NA
-
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
NCT02080026 ·Status: COMPLETED ·Phase: NA
-
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
NCT07235033 ·Status: COMPLETED ·Phase: PHASE2
-
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
NCT04619823 ·Status: RECRUITING ·Phase: NA
-
Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield
NCT05540470 ·Status: COMPLETED ·Phase: NA
-
Anti-malaria MAb in Kenyan Children
NCT05400655 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
NCT00703924 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Protective Efficacy of Pb(PfCS@UIS4)
NCT03138096 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Collection of Biological Material From Pregnant Women in a Malarial Region
NCT01862783 ·Status: TERMINATED
-
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
NCT00414336 ·Status: COMPLETED ·Phase: PHASE1
-
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
NCT02639299 ·Status: RECRUITING
-
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
NCT01300975 ·Status: COMPLETED ·Phase: PHASE2